TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02879318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT03025321

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
Study: NCT03415152

Intervention type: DRUG
Intervention: Omacor (Omega-3-acid ethyl esters)
Description: Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Study: NCT03614104

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mobile Health Technology (short message service)
Description: Health education through mobile technology with Short Message Service (SMS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Health Technology (short message service)
Description: Health education through mobile technology with Short Message Service (SMS)
Study: NCT01441869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onglyza (saxagliptin)
Description: Oral tablets, 5 mg , single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onglyza (saxagliptin)
Description: Oral tablets, 5 mg , single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diabex
Description: Extended release oral tablets, 1000 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin/1000 mg metformin
Description: Extended release fixed dose combination tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diabex
Description: Extended release oral tablets, 500 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin/500 mg metformin
Description: Extended release fixed dose combination tablet, single dose
Study: NCT00889629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Description: Active group receives doxercalciferol (Hectorol) 1mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 25-OH Vitamin D3
Description: All groups received cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25-OH Vitamin D3
Description: All groups received cholecalciferol
Study: NCT04591639

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 milligrams [Farxiga]
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 milligrams [Farxiga]
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
Study: NCT01095172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m\^2, single dose given 2-4 weeks prior to transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: dose calculated to give levels of 3-7ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dose calculated to give levels of 3-7ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil 2g/day in divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil 2g/day in divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
Study: NCT01738945

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: 10 mg/day for 12 weeks
Study: NCT03163446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF-301
Description: CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given as a single 2 hour iv infusion
Study: NCT00002551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: See arm assignments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: See arm assignments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: See arm assignments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: See arm assignments.
Study: NCT06064539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: Tablet, taken orally
Study: NCT00002551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole hydrochloride
Description: See arm assignments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: See arm assignments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: See arm assignments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: See arm assignments.
Study: NCT04787367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine.
Study: NCT01251952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox (Ontak)
Description: After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360.
Study: NCT04779424

Intervention type: OTHER
Intervention: POCT
Description: Capillary blood sample antibody point of care test
Study: NCT00379834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: Cosopt twice daily in both eyes
Study: NCT00648180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate Tablets 100 mg
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoxa Tablets 100 mg
Description: 100mg, single dose fed
Study: NCT03884881

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: metagenomic next generation sequencing
Description: Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conventional pathogen detection
Description: Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics

Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem，Imipenem，Caspofene，Osstat
Description: Meropenem，Imipenem，Caspofene，Osstat

Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem，Imipenem，Caspofene，Osstat
Description: Meropenem，Imipenem，Caspofene，Osstat
Study: NCT01595373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyl ghrelin
Description: Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ringer acetate)
Description: Ringer acetate 2 microliter/min for 300 minutes
Study: NCT02935556

Intervention type: OTHER
Intervention: no intervention
Description: database and epigenetic study

Intervention type: OTHER
Intervention: no intervention
Description: database and epigenetic study
Study: NCT01336725

Intervention type: BEHAVIORAL
Intervention: Teaching life style changes
Description: Single group: Teaching, group sessions, physical activity

Intervention type: OTHER
Intervention: Active participation
Description: Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.

Intervention type: OTHER
Intervention: Teaching
Description: Morbid obesity group attend 40 hours of group sessions
Study: NCT00230035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous CD34+HPC transplantation (HSCT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit anti-thymocyte globulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth colony stimulating factor (G-CSF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Study: NCT01001429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
Study: NCT04125069

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Graft (CABG)
Description: Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
Study: NCT06135181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
Description: 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
Description: 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: 0.9% sodium chloride by intravenous injection (at 2 mL/s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: 0.9% sodium chloride by intravenous injection (at 2 mL/s)
Study: NCT03904823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib po
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296 po
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
Study: NCT01299558

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate//GW642444
Description: Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate
Description: Single IV dose of FF (250mcg)

Intervention type: DRUG
Group type: OTHER
Intervention: GW642444
Description: Single IV dose of GW642444 (55mcg)
Study: NCT01347463

Intervention type: PROCEDURE
Intervention: SCM triangle - ipsilateral nipple
Description: draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
Study: NCT00643760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: gabapentin enacarbil 1200mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 2400mg/day
Description: gabapentin enacarbil 2400mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: gabapentin enacarbil 3600mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: pregabalin 300mg/day
Study: NCT04600869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturalistic Decision-Making Model-based Oncofertility Care Education
Description: We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
Study: NCT04268160

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure GPx activity
Description: Routine blood draw to measure levels of blood markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure GPx activity
Description: Routine blood draw to measure levels of blood markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure SOD activity
Description: Routine blood draw to measure levels of blood markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure SOD activity
Description: Routine blood draw to measure levels of blood markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure Lp(a) levels
Description: Routine blood draw to measure levels of blood markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw to measure Lp(a) levels
Description: Routine blood draw to measure levels of blood markers.
Study: NCT01053741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled autologous seminal fluid
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled autologous seminal fluid
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled Normosol-R
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiolabeled Normosol-R
Description: Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
Study: NCT02244983

Intervention type: OTHER
Intervention: Patients History
Description: History taking and drawing of a blood sample
Study: NCT05030116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenqu Xiaoshi oral liquid
Description: Shenqu Xiaoshi oral liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone suspension
Description: Domperidone suspension
Study: NCT00619827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR grass pollen allergen extract tablet
Description: 300 IR grass pollen allergen extract tablet once daily during four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet once daily during four months
Study: NCT03110107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986218
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT01386606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsule oral~1X a day 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsule oral~1X a day 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal (enclomiphene citrate)
Description: capsule oral~1X a day 6 weeks
Study: NCT06064539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Tablet, taken orally
Study: NCT02249598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lactamica
Study: NCT01386606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: topical gel~1X a day 6 weeks
Study: NCT01530269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11-Sodium Acetate
Description: PET Imaging with C11-Sodium Acetate
Study: NCT02112942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX21459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX21459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX21459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study: NCT01241474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates
Description: 6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maize (corn) oil
Description: 6 x 1g capsules per day for 9 months
Study: NCT04065490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valeda PBM treatment
Description: The Valeda Light Delivery System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Valeda Sham treatment
Description: The sham mode of the Valeda Light Delivery System.
Study: NCT04273321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 1mg/kg/day ivgtt for 7 days.
Study: NCT02221752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate + folic acid
Description: Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.